Evotec SE set the stage for a further expansion of its drug discovery and development business in the first half year while increasing revenue from its traditional service business. Group revenue was up by 16% to €207.1 million while operating profit rose by 11% to €24 million. The strong first half performance triggered an upgrade in the company’s guidance for 2019.
